PRESS RELEASE:

Spectrum Collaborates with UCLA on Saliva-Based Next-Gen Sequencing (NGS) Liquid Biopsy Research for the Early Detection of Lung Cancer

Leslie Titus Bryant, Director of Marketing & Brand
January 27, 2021

Study to focus on using saliva in the analysis of cell-free circulating tumor DNA (ctDNA) to accurately and non-invasively detect non-small cell lung cancer (NSCLC).

Spectrum Solutions, LLC today announced its sponsored research collaboration with the UCLA School of Dentistry for a study on using saliva in early lung cancer detection and analysis. Spectrum has funded a study that aims to recruit 50 patients with lung cancer and seeks to validate saliva’s tumor-specific ctDNA detection sensitivity and positive agreement against tissue biopsy-based genotyping. Saliva will be collected, preserved, and transported for DNA testing using Spectrum’s Saliva Collection System. The company will further support the development of clinical methods and additional technical innovations.

The study is being led by professor of oral biology, Dr. David Wong, from the UCLA School of Dentistry, a research-intensive dental school and the lead U.S. research site for the study.

“Saliva-based liquid biopsy ctDNA detection can be used to not only provide an accurate cancer diagnosis, but additionally track the actionable mutations, monitor a response to treatments, and assess the emergence of drug resistance,” Dr. Wong said. “This study’s non-invasive use of saliva for the analysis of ctDNA will prove to overcome current limitations, provide procedures that improve detection sensitivity, and offer significant clinical impact on early detection, risk assessment, screening, diagnosis, and personalized/precision medicine.”

The research study will compare saliva and plasma samples from NSCLC patients to identify usctDNA molecules in saliva and use special extraction methods to improve overall sensitivity of current liquid biopsy procedures.

“At Spectrum Solutions, we are proud to sponsor Dr. Wong and UCLA in this exciting research project to unlock and harness the potential of saliva as a primary diagnostic resource to combat and improve the lives and wellbeing of people around the world,” said Stephen Fanning, President, and CEO of Spectrum Solutions. “We look forward to working with the innovative researchers at UCLA and pledge our full support.”

ABOUT THE UCLA SCHOOL OF DENTISTRY

The UCLA School of Dentistry is dedicated to improving the oral health of the people of California, the nation, and the world. It has an international reputation for its teaching, research, patient care, and public service initiatives. The school provides education and training that develop leaders; conducts research programs that generate new knowledge; and delivers patient‑centered oral health care to the community and state.

PRESS RELEASE:

Spectrum Collaborates with UCLA on Saliva-Based Next-Gen Sequencing (NGS) Liquid Biopsy Research for the Early Detection of Lung Cancer

Leslie Titus Bryant, Director of Marketing & Brand
January 27, 2021

Study to focus on using saliva in the analysis of cell-free circulating tumor DNA (ctDNA) to accurately and non-invasively detect non-small cell lung cancer (NSCLC).

Spectrum Solutions, LLC today announced its sponsored research collaboration with the UCLA School of Dentistry for a study on using saliva in early lung cancer detection and analysis. Spectrum has funded a study that aims to recruit 50 patients with lung cancer and seeks to validate saliva’s tumor-specific ctDNA detection sensitivity and positive agreement against tissue biopsy-based genotyping. Saliva will be collected, preserved, and transported for DNA testing using Spectrum’s Saliva Collection System. The company will further support the development of clinical methods and additional technical innovations.

The study is being led by professor of oral biology, Dr. David Wong, from the UCLA School of Dentistry, a research-intensive dental school and the lead U.S. research site for the study.

“Saliva-based liquid biopsy ctDNA detection can be used to not only provide an accurate cancer diagnosis, but additionally track the actionable mutations, monitor a response to treatments, and assess the emergence of drug resistance,” Dr. Wong said. “This study’s non-invasive use of saliva for the analysis of ctDNA will prove to overcome current limitations, provide procedures that improve detection sensitivity, and offer significant clinical impact on early detection, risk assessment, screening, diagnosis, and personalized/precision medicine.”

The research study will compare saliva and plasma samples from NSCLC patients to identify usctDNA molecules in saliva and use special extraction methods to improve overall sensitivity of current liquid biopsy procedures.

“At Spectrum Solutions, we are proud to sponsor Dr. Wong and UCLA in this exciting research project to unlock and harness the potential of saliva as a primary diagnostic resource to combat and improve the lives and wellbeing of people around the world,” said Stephen Fanning, President, and CEO of Spectrum Solutions. “We look forward to working with the innovative researchers at UCLA and pledge our full support.”

ABOUT THE UCLA SCHOOL OF DENTISTRY

The UCLA School of Dentistry is dedicated to improving the oral health of the people of California, the nation, and the world. It has an international reputation for its teaching, research, patient care, and public service initiatives. The school provides education and training that develop leaders; conducts research programs that generate new knowledge; and delivers patient‑centered oral health care to the community and state.

Press Release Header- UCLA - DR WONG Research Study Liquid Biopsy for Eary Detection of Lung Cancer

Access this press release on Business Wire

Our Team, Helping your Team, get Back in the Game!

How you collect saliva makes a big diagnostic difference.
Real-world mass testing scenarios require an authorized, proven, and supported system that mitigates any risk of exposure and a company that holds a blackbelt in scalability.
Get your business back in the game.

blank

PROUD PARTNER OF MLB

™/© 2020 MLB

Get to Know Our #PartoftheSolution

Who is Spectrum Solutions?

Headquartered in Salt Lake City, Utah, Spectrum is a life science, medical device manufacturing company focusing its fully-integrated industry expertise on creating forward-looking, and scalable, end-to-end solutions for clinical diagnostic projects and commercialized product plans. A single-source provider of innovative medical device engineering & product manufacturing, molding, chemical formulation, packaging design, customized kitting, & direct-to-user fulfillment, Spectrum’s bio-sample collection devices, patented technologies, and dedicated services deliver measurable process optimization, unprecedented efficiency, and unmatched global scalability.

#partoftheSolution

Leslie Titus Bryant Spectrum Solutions SpokesmanSpectrum Corporate Spokesman
Leslie Titus Bryant
Director of Marketing & Brand
admin@spectrumsolution.com

Tim Rush Public Relations, Springboard 5Media Contact
Tim Rush, Springboard5
801-208-1100
tim.rush@springboard5.com

Get to Know Our #PartoftheSolution

Who is Spectrum Solutions?

Headquartered in Salt Lake City, Utah, Spectrum Solutions is a life science and medical device manufacturing company that focuses its fully-integrated industry expertise on creating forward-looking and scalable end-to-end solutions for clinical diagnostic projects and commercialized product plans. Spectrum is a single-source provider of innovative medical device engineering & product manufacturing, molding, chemical formulation, packaging design, customized kitting, & direct-to-user fulfillment. Its bio-sample collection devices, patented technologies, and dedicated services deliver measurable process optimization, unprecedented efficiency, and unmatched global scalability.

#partoftheSolution

Leslie Titus Bryant Spectrum Solutions SpokesmanSpectrum Corporate Spokesman
Leslie Titus Bryant
Director of Marketing & Brand
admin@spectrumsolution.com

Tim Rush Public Relations, Springboard 5Media Contact
Tim Rush, Springboard5
801-208-1100
tim.rush@springboard5.com

Spectrum
in the News

Spectrum
in the News

Slide Predict, Diagnose, & Prevent Saliva-Based Diagnostic Solutions #SpitMatters blank

Health is a dynamic state of wellbeing. Healthcare providers and researchers have long believed that changes in our saliva record our ongoing state-of-health story. This encrypted source of individual truth, and how to best use it, delivers us all a quicker path to informed decisions and treatments free of adverse reactions.

Interestingly, saliva acts as a wide resource of genomic information useful for identifying and monitoring in real-time a disease as well as its state of progression. Saliva analysis looks at the cellular level, the biologically active compounds, making it a true representative of what is clinically relevant.

Spectrum’s technically-superior saliva collection systems have not only been engineered to lead the saliva collection industry in molecular diagnostics and clinical research applications but deliver the safest, most robust biomaterial for the earliest detection and diagnosis of disease and infection.

  • Saliva provides the earliest path to critical detection and diagnosis
  • Saliva contains the entire library of proteins, hormones, antibodies, and other molecular compounds measured in routine blood tests
  • First EUA authorized saliva collection device for COVID-19 testing & authorized device for direct-to-patient at-home sample self-collection
  • Used in supervised & unsupervised sample collection LDT workflows of symptomatic & asymptomatic users
  • Pain-free, non-invasive, & safe – ideal for those needing frequent & repeat testing
  • In-device live virus inactivation at ambient temps (COVID-19 EUA validated data)
  • Eliminates hooded containment of samples arriving at the testing lab
  • No temperature-controlled storage or transport of collected saliva samples
  • Single device for DNA & viral RNA applications
  • Safest collection approach & most robust biomaterial for detecting COVID-19
  • Delivers 99.998% highest levels of testing accuracy & sensitivity
  • Formulation identifies infections at its earliest stage from as few as 200 copies/ml (lateral flow rapid tests need 10,000-20,000 copies/ml)
  • A single preserved saliva sample provides opportunity for multiple tests
  • Over two weeks of post-collection stability with no degradation in sample efficacy
  • System maintains critical bio-sample consistency
  • Mass-testing scalability & easy device integration using validated and supported processes
  • Mitigates any risk of infection throughout the testing process
  • Pinpoint life-cycle stage of active viral infection
  • Eliminates UN3373 shipping designation with clearance from USPS, FedEx, & UPS
  • Delivers the highest levels of testing accuracy using qualified extraction chemistries
Questions? Let’s Connect
Contact Us

Are you a lab?
Let’s connect.

#partofthesolution

How can we help?
Let’s Chat

Looking for a customized testing or life science product solution? Benefit from our experience, industry understanding, and process support.